All Pharma News
INmune Bio XPro™ Compassionate Use Update in Alzheimer`s

INmune Bio XPro™ Compassionate Use Update in Alzheimer`s
GLOBENEWSWIRE
30 Apr 2024
Share Share
INmune Bio Initiates 2nd Cohort of INKmune™ in mCRPC Study

INmune Bio Initiates 2nd Cohort of INKmune™ in mCRPC Study
GLOBENEWSWIRE
29 Apr 2024
Share Share
INmune Announces $9.7M Registered Direct Offering

INmune Announces $9.7M Registered Direct Offering
GLOBENEWSWIRE
25 Apr 2024
Share Share
INmune Bio Announces 24-Month Stability Valid of XPro™ for Phase III Readiness

INmune Bio Announces 24-Month Stability Valid of XPro™ for Phase III Readiness
PRESS RELAESE
23 Apr 2024
Share Share
INmune Bio Announces 24-Month XPro Stability, Phase 3 Readiness Modeling

INmune Bio Announces 24-Month XPro Stability, Phase 3 Readiness Modeling
GLOBENEWSWIRE
23 Apr 2024
Share Share
INmune $4.8M Direct With 20% Insider Participation

INmune $4.8M Direct With 20% Insider Participation
GLOBENEWSWIRE
22 Apr 2024
Share Share
INmune Presents Data on INB03`s at AACR 2024

INmune Presents Data on INB03`s at AACR 2024
GLOBENEWSWIRE
08 Apr 2024
Share Share
INmune Bio Inc. Announces Year End 23 Results and Provides a Q4 Business Update

INmune Bio Inc. Announces Year End 23 Results and Provides a Q4 Business Update
GLOBENEWSWIRE
28 Mar 2024
Share Share
INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results

INmune Bio Inc. to Report Fourth Quarter 2023 Financial Results
GLOBENEWSWIRE
26 Mar 2024
Share Share
INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT

INmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT
GLOBENEWSWIRE
13 Mar 2024
Share Share